menu
    • menu
    [{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Celltrion","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Celltrion"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":1.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.25,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Teijin Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Teijin Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":1.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.25,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Teijin Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Teijin Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Alogliptin

    Menu

    Alogliptin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Takeda Pharmaceutical

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alogliptin Benzoate,Pioglitazone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Teijin Pharma

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited

                            Details : The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.

                            Brand Name : Liovel

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 01, 2021

                            Lead Product(s) : Alogliptin Benzoate,Pioglitazone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Teijin Pharma

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Takeda Pharmaceutical

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alogliptin Benzoate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Teijin Pharma

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited

                            Details : The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.

                            Brand Name : Nesina

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 26, 2021

                            Lead Product(s) : Alogliptin Benzoate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Teijin Pharma

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Takeda Pharmaceutical

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alogliptin Benzoate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Celltrion

                            Deal Size : $278.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda to Divest Select APAC Assets to Celltrion for $278M

                            Details : The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products such as Nesina® and Edarbi® and Products in a variety of indications.

                            Brand Name : Nesina

                            Molecule Type : Small molecule

                            Upfront Cash : $266.0 million

                            June 11, 2020

                            Lead Product(s) : Alogliptin Benzoate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Celltrion

                            Deal Size : $278.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth